Literature DB >> 16670343

CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury.

Yuan Zhai1, Xiu-da Shen, Wayne W Hancock, Feng Gao, Bo Qiao, Charles Lassman, John A Belperio, Robert M Strieter, Ronald W Busuttil, Jerzy W Kupiec-Weglinski.   

Abstract

Ischemia-reperfusion injury (IRI), an innate immune-dominated inflammatory response, develops in the absence of exogenous Ags. The recently highlighted role of T cells in IRI raises a question as to how T lymphocytes interact with the innate immune system and function with no Ag stimulation. This study dissected the mechanism of innate immune-induced T cell recruitment and activation in rat syngeneic orthotopic liver transplantation (OLT) model. Liver IRI was induced after cold storage (24-36 h) at 4 degrees C in University of Wisconsin solution. Gene products contributing to IRI were identified by cDNA microarray at 4-h posttransplant. IRI triggered increased intrahepatic expression of CXCL10, along with CXCL9 and 11. The significance of CXCR3 ligand induction was documented by the ability of neutralizing anti-CXCR3 Ab treatment to ameliorate hepatocellular damage and improve 14-day survival of 30-h cold-stored OLTs (95 vs 40% in controls; p < 0.01). Immunohistology analysis confirmed reduced CXCR3+ and CD4+ T cell infiltration in OLTs after treatment. Interestingly, anti-CXCR3 Ab did not suppress innate immune activation in the liver, as evidenced by increased levels of IL-1beta, IL-6, inducible NO synthase, and multiple neutrophil/monokine-targeted chemokine programs. In conclusion, this study demonstrates a novel mechanism of T cell recruitment and function in the absence of exogenous Ag stimulation. By documenting that the execution of innate immune function requires CXCR3+CD4+ T cells, it highlights the critical role of CXCR3 chemokine biology for the continuum of innate to adaptive immunity in the pathophysiology of liver IRI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16670343     DOI: 10.4049/jimmunol.176.10.6313

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation.

Authors:  Benjamin H Friedman; Joshua H Wolf; Liqing Wang; Mary E Putt; Abraham Shaked; Jason D Christie; Wayne W Hancock; Kim M Olthoff
Journal:  Liver Transpl       Date:  2012-02       Impact factor: 5.799

Review 2.  Ischemia-reperfusion and immediate T cell responses.

Authors:  Yanfei Huang; Hamid Rabb; Karl L Womer
Journal:  Cell Immunol       Date:  2007-10-17       Impact factor: 4.868

Review 3.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

4.  High renal ischemia temperature increases neutrophil chemoattractant production and tissue injury during reperfusion without an identifiable role for CD4 T cells in the injury.

Authors:  Nobuyuki Fukuzawa; Austin D Schenk; Marianne Petro; Katsuya Nonomura; William M Baldwin; Robert L Fairchild
Journal:  Transpl Immunol       Date:  2009-08-05       Impact factor: 1.708

Review 5.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

6.  Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance.

Authors:  Anil Dangi; Tina L Sumpter; Shoko Kimura; Donna B Stolz; Noriko Murase; Giorgio Raimondi; Yoram Vodovotz; Chao Huang; Angus W Thomson; Chandrashekhar R Gandhi
Journal:  J Immunol       Date:  2012-03-16       Impact factor: 5.422

7.  Recipient T cell TIM-3 and hepatocyte galectin-9 signalling protects mouse liver transplants against ischemia-reperfusion injury.

Authors:  Yuanxing Liu; Haofeng Ji; Yu Zhang; Xiuda Shen; Feng Gao; Xiangyi He; Gabriella A Li; Ronald W Busuttil; Vijay K Kuchroo; Jerzy W Kupiec-Weglinski
Journal:  J Hepatol       Date:  2014-10-31       Impact factor: 25.083

Review 8.  Targeting iNKT cells for the treatment of sickle cell disease.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Clin Immunol       Date:  2011-03-22       Impact factor: 3.969

Review 9.  Molecular mediators of liver ischemia and reperfusion injury: a brief review.

Authors:  Andrew J Vardanian; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

Review 10.  Inflammatory targets of therapy in sickle cell disease.

Authors:  Amma Owusu-Ansah; Chibueze A Ihunnah; Aisha L Walker; Solomon F Ofori-Acquah
Journal:  Transl Res       Date:  2015-07-11       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.